Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30.
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.
组蛋白甲基转移酶 EZH2 自首次发现其在转移性前列腺癌中表达升高以来，已经成为癌症表观遗传学领域的焦点十年。由于其在癌症发展过程中的重要作用及其作为有效治疗靶点的潜力，它仍然吸引着大量的科学关注。因此，我们在这里回顾了 EZH2 在前列腺癌中的失调、它的功能、上游调节剂、下游效应物以及 EZH2 靶向方法的现状。因此，本综述提供了 EZH2 在前列腺癌中的全面概述。
